


Ivabradine

Cat. No.:	HY-B0162
CAS No.:	155974-00-8
Molecular Formula:	C ₂₇ H ₃₆ N ₂ O ₅
Molecular Weight:	468.59
Target:	HCN Channel
Pathway:	Membrane Transporter/Ion Channel
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Ivabradine is a potent and orally active HCN (hyperpolarization-activated cyclic nucleotide-gated) channel blocker that inhibits the cardiac pacemaker current (I _f). Ivabradine reduces dose-dependently heart rate without modification of blood pressure. Ivabradine shows anticonvulsant, anti-ischaemic and anti-anginal activity ^{[1][2][3][4]} .																
In Vivo	<p>Ivabradine (1, 10, 20 mg/kg; i.p.) shows anticonvulsant and neuroprotective action in mice^[3]. Ivabradine (5, 10, 20 mg/kg;p.o.; daily for 1 weeks) lowers heart rate in mice with enhanced sympathoadrenergic activities^[4]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>25-30 g, 6 weeks male Swiss mice^[3]</td> </tr> <tr> <td>Dosage:</td> <td>1, 10, 20 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>i.p.; for 3 days</td> </tr> <tr> <td>Result:</td> <td>Attenuated PTZ- and PICRO-induced seizures while presented an antioxidant effect in allbrain areas studied, and reduced cleaved caspase-3 expression in the CA1 and DG region of PICRO- and PTZ-treated mice, respectively.</td> </tr> <tr> <td>Animal Model:</td> <td>3-4 months transgenic (TG) mice with cardiac-restricted overexpression of b2AR^[4]</td> </tr> <tr> <td>Dosage:</td> <td>5, 10, 20 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>P.o; daily for 1 weeks</td> </tr> <tr> <td>Result:</td> <td>Reduced the maximal HR increase in response to the b-agonist isoproterenol, without modifying the response of contractile parameters at 10 mg/kg.</td> </tr> </table>	Animal Model:	25-30 g, 6 weeks male Swiss mice ^[3]	Dosage:	1, 10, 20 mg/kg	Administration:	i.p.; for 3 days	Result:	Attenuated PTZ- and PICRO-induced seizures while presented an antioxidant effect in allbrain areas studied, and reduced cleaved caspase-3 expression in the CA1 and DG region of PICRO- and PTZ-treated mice, respectively.	Animal Model:	3-4 months transgenic (TG) mice with cardiac-restricted overexpression of b2AR ^[4]	Dosage:	5, 10, 20 mg/kg	Administration:	P.o; daily for 1 weeks	Result:	Reduced the maximal HR increase in response to the b-agonist isoproterenol, without modifying the response of contractile parameters at 10 mg/kg.
Animal Model:	25-30 g, 6 weeks male Swiss mice ^[3]																
Dosage:	1, 10, 20 mg/kg																
Administration:	i.p.; for 3 days																
Result:	Attenuated PTZ- and PICRO-induced seizures while presented an antioxidant effect in allbrain areas studied, and reduced cleaved caspase-3 expression in the CA1 and DG region of PICRO- and PTZ-treated mice, respectively.																
Animal Model:	3-4 months transgenic (TG) mice with cardiac-restricted overexpression of b2AR ^[4]																
Dosage:	5, 10, 20 mg/kg																
Administration:	P.o; daily for 1 weeks																
Result:	Reduced the maximal HR increase in response to the b-agonist isoproterenol, without modifying the response of contractile parameters at 10 mg/kg.																

CUSTOMER VALIDATION

- J Cell Physiol. 2019 Feb;234(2):1925-1936.

-
- Front Pharmacol. 2021 Jun 22;12:696635.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Tardif JC, et al. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005 Dec;26(23):2529-36.
- [2]. Mulder P, et al. Heart rate slowing for myocardial dysfunction/heart failure. Adv Cardiol. 2006;43:97-105.
- [3]. Cavalcante TMB, et al. Ivabradine possesses anticonvulsant and neuroprotective action in mice. Biomed Pharmacother. 2019 Jan;109:2499-2512.
- [4]. Du XJ, et al. I(f) channel inhibitor ivabradine lowers heart rate in mice with enhanced sympathoadrenergic activities. Br J Pharmacol. 2004 May;142(1):107-12.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA